Loading clinical trials...
Loading clinical trials...
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of ALKS 9072 in Subjects With Acute Exacerbation of Schizophrenia
Conditions
Interventions
ALKS 9072
Placebo
Locations
84
United States
Alkermes Investigational Site
Little Rock, Arkansas, United States
Alkermes Investigational Site
Little Rock, Arkansas, United States
Alkermes Investigational Site
Springdale, Arkansas, United States
Alkermes Investigational Site
Cerritos, California, United States
Alkermes Investigational Site
Garden Grove, California, United States
Alkermes Investigational Site
La Habra, California, United States
Start Date
December 1, 2011
Primary Completion Date
January 1, 2014
Completion Date
March 1, 2014
Last Updated
January 30, 2019
NCT06894212
NCT04226898
NCT05240976
NCT06745479
NCT05304767
NCT07455929
Lead Sponsor
Alkermes, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions